Anuh Pharma Q4 FY26 Results: PAT Rs 12 Cr

Anuh Pharma Q4 FY26 results were declared on May 20, 2026. The company reported PAT of Rs 12 crore for the quarter ended March 31, 2026, down 0% YoY compared to Rs 12 crore in Q4 FY25. Revenue from operations stood at Rs 202 crore, up 2% YoY. Gross profit was Rs 17 crore (+6%). Results are on a Standalone basis. Anuh Pharma is a Pharmaceuticals and APIs company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Anuh Pharma Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	202	198	+2%
Gross Profit	17	16	+6%
Net Profit	12	12	+0%
Basis	Standalone

Note: Anuh Pharma Q4 FY26 results declared May 20, 2026. Verify from BSE/NSE audited filings before making investment decisions.

Anuh Pharma Q4 FY26 Performance Analysis

The Anuh Pharma Q4 FY26 results reflect the company’s performance in the January to March 2026 quarter. The quarter demonstrates stable operational delivery. Anuh Pharma operates in the Pharmaceuticals and APIs sector, a segment supported by India’s GDP growth above 6.5% and domestic demand momentum in FY26.

Revenue growth of 2% YoY to Rs 202 crore demonstrates continued business momentum for Anuh Pharma in Q4 FY26.

Screen the best stocks on the Univest Screener.

Key Factors Driving Anuh Pharma Q4 FY26 Results

Revenue Performance

Anuh Pharma Q4 FY26 revenue of Rs 202 crore was up 2% YoY. Revenue momentum reflects steady demand conditions in the Pharmaceuticals and APIs sector.

Profitability and Margins

The Anuh Pharma Q4 FY26 PAT of Rs 12 crore (down 0% YoY) reflects stable earnings delivery in a competitive environment.

India Macro Tailwinds Q4 FY26

The January to March 2026 quarter was supported by India’s robust macroeconomic environment with GDP above 6.5%, government capex continuity at Rs 11.21 lakh crore in the Union Budget FY27, and strong domestic consumption. The Reserve Bank of India’s accommodative policy stance supported credit and demand conditions. For Anuh Pharma, operating in the Pharmaceuticals and APIs sector, these macro conditions provided a constructive backdrop during the quarter ended March 31, 2026.

FY27 Outlook

Following Anuh Pharma Q4 FY26 results, investor focus will shift to FY27 revenue guidance, margin improvement roadmap, capital allocation plans, and management commentary on demand visibility. The Pharmaceuticals and APIs sector continues to benefit from India’s structural growth, rising consumption, and investment cycle. Sustaining the growth momentum and expanding margins will be the key priorities for management in FY27.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on Anuh Pharma Q4 FY26

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.